News und Analysen
Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200113005846/en/
(Photo: Business Wire)
Ipsen (Euronext: IPN; ADR
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2019 following the close of market on Wednesday, January 29, 2020.
On the same day, at
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2019 following the close of market on Wednesday, January 29, 2020.
On the same day, at
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2019 following the close of market on Wednesday, January 29, 2020.
On the same day, at
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year
Lantheus Holdings Announces Senior Leadership Appointment
Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative
ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health
Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its Chief Executive Officer and President, Alan H. Auerbach, will be presenting at the 38th Annual J.P. Morgan
Waters to Acquire Andrew Alliance
Waters Corporation (NYSE:WAT) announced today that it has entered into a definitive agreement to acquire Andrew Alliance, an innovator in specialty laboratory automation technology, including
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be
Novus Therapeutics Provides Update on OP0201
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the
Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2019. Novocure plans to discuss these
Morphosys: Milliarden für Anti-Krebs-Blockbuster
Morphosys-Aktien (WKN: 663200) steigen im Xetra-Handel auf bis zu 146,30 Euro. Grund ist ein milliardenschwerer Deal für den firmeneigenen Anti-Krebs-Wirkstoff Tafasitamab mit dem Biopharma-Bluechip
Morphosys: Milliarden für Anti-Krebs-Blockbuster
Morphosys-Aktien (WKN: 663200) steigen im Xetra-Handel auf bis zu 146,30 Euro. Grund ist ein milliardenschwerer Deal für den firmeneigenen Anti-Krebs-Wirkstoff Tafasitamab mit dem Biopharma-Bluechip
NanoString Provides Preliminary Operational and Financial Results for Fourth Quarter and FY 2019
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today provided preliminary operational and financial results for the fourth quarter
Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the
Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein
Illumina, Inc. (NASDAQ: ILMN) gab heute bekannt, dass das Unternehmen zwei weitere Patentverletzungsklagen im Zusammenhang mit den Sequenzierprodukten von BGI, einschließlich des DNBSeq-400 (auch
Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein
Illumina, Inc. (NASDAQ: ILMN) gab heute bekannt, dass das Unternehmen zwei weitere Patentverletzungsklagen im Zusammenhang mit den Sequenzierprodukten von BGI, einschließlich des DNBSeq-400 (auch
Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein
Illumina, Inc. (NASDAQ: ILMN) gab heute bekannt, dass das Unternehmen zwei weitere Patentverletzungsklagen im Zusammenhang mit den Sequenzierprodukten von BGI, einschließlich des DNBSeq-400 (auch